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Section 1: Abstract
Relationship Between Preoperative Statin Use And Postoperative Infectious
Complications in General and Non-Cardiac Surgery
Johnathan A. Bernard1,2, Ronnie A. Rosenthal1, Selwyn O. Rogers2
1: Department of Surgery, West Haven VA Medical Center, Yale University School of
Medicine, New Haven, CT
2: Center for Surgery and Public Health, Harvard School of Public Health, Boston, MA

Objective:
Characterize the impact of preoperative statin use on postoperative infectious
complications and 30-day postoperative mortality in general and non-cardiac surgery
patients.
Background:
The lipid lowering effects of statins have been well documented for the treatment of
coronary artery disease. There has been mounting evidence to support use of statins for
their pleiotropic effect. Among these, immune system modulation, improved endothelial
function, attenuation of sepsis, and organ protection are particularly relevant to the
surgical patient. However, the pleiotropic effects of statins are poorly understood
postoperatively in general and non-cardiac surgery patients.
Design:
Retrospective observational study conducted to test the hypothesis that preoperative statin
use leads to a risk reduction of postoperative infectious complications (POIC) (any
occurrence of surgical site infection, deep surgical site infection, wound dehiscence,
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pneumonia, urinary tract infection, sepsis, or septic shock) and would reduce the risk of
30 day postoperative mortality, while identifying independent risk factors for POIC. To
do so, the ACS NSQIP database at a 777-bed academic medical center was merged with
pharmacy data and electronic medical records at the same institution from January 1,
2006 to January 1, 2008.
Results:
Two thousand, five hundred and eighty four patients underwent major general and noncardiac surgery during the study time period. Five hundred and seventy eight of these
patients were on statin therapy before admission and continued statin therapy after
surgery. A total of two hundred and twenty four POIC occurred. Best-fit logistic
regression models demonstrated that ASA classification, length of operation, and
emergent status of case were associated with an increase in POIC. Patients receiving
statins, when adjusted for ASA classification, length of operation, and case emergency,
did not have a reduced risk of POIC, with an AOR 0.978 (95% CI 0.58 – 1.63, p = 0.93).
Statin use was, however, associated with a reduction in 30 day postoperative mortality
(OR 0.45; 95% CI 0.23 – 0.87, p = 0.019).
Conclusion:
Preoperative statin therapy reduces the risk of 30 day mortality, but its effect on reducing
POIC after general surgery remains to be proven. Further research is needed to evaluate
the role of preoperative statin therapy and its pleiotropic effects in surgical patients.
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Section 4: Introduction
Infections and Surgery
Postoperative complications remain a dreaded result of surgical procedures. Such
complications increase morbidity of patients, increase utilization of medical resources
and increase the overall cost of delivering health care 1, 2. Researchers have found that
infectious, cardiovascular, respiratory, and thromboembolic complications could account
for an increase of upwards of $11,626 or more in the health care expenditure of a surgical
patient 3. The prevalence of infectious complications in surgery has been reported to be
around 13.3%, with surgical site infections (SSI) accounting for 2-5% 4, 5. In 2005, 45
million surgical operations were performed in the U.S. alone; extrapolated cost,
morbidity, and allocation of resources toward postoperative complications are staggering
6. Much attention has been dedicated to the reduction and elimination of postoperative
complications 4, 7-13. Efforts to reduce surgical infections have included surgical
checklists, a Surgical Apgar Score, prophylactic antibiotic treatment, and controlling
glucose levels both acutely and chronically 9, 10, 13-16.

Recent literature has suggested that 3-hydroxy-3-methylglutaryl-coenzyme A reductase
inhibitors (HMG CoA reductase inhibitors), commonly known as statins, may have a role
in mitigating sepsis and baceteremia in patients in intensive care units and have a role in
decreasing mortality in surgical patients undergoing cardiac surgery 17-29. Researchers
have theorized that the cholesterol-independent effects of statins are the result of blocking
other products in the mevalonte pathway, but clinically the results are poorly understood.
The use of statins for these purposes are in stark contrast to their initial hypothesized
mechanism of action and clinical benefit.
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3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (Statins)
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) are a
class of medications that block low density lipoprotein (LDL) cholesterol biosynthesis by
inhibiting conversion of HMG-CoA to mevalonate 30, 31. Inhibiting this rate-limiting
step in LDL cholesterol biosynthesis results in an overall decrease in circulating serum
cholesterol levels. The decreased concentrations of mevalonate cause a negative
feedback loop that drives the increase production of LDL cholesterol receptors (LDLr) in
hepatocytes. Statins, therefore, induce LDLr mRNA production in the cell that leads to
up-regulation of LDLr on the surface of the cell 32. The decreased availability of
cholesterol in the cell drives the extraction circulating serum LDL cholesterol. This leads
to a decrease of serum LDL cholesterol, the clinically apparent effect of statin therapy
33-36.

In addition to blocking mevalonic acid, statins block all down stream products in the
cholesterol biosynthesis pathway. The main products blocked other than mevalonate are
isoprenylated protein intermediates. Isoprenoid intermediates, including
farnesylpyrophosphate (FPP) and geranylgeranylpyrophosphate (GGPP), have a role in
the post-translational modification of several key proteins, which allows the proteins the
ability of covalent attachment, subcellular localization, and intracellular trafficking in the
cell 19. Both FPP and GGPP have important effects on GTP-binding proteins, in
particular the subgroup of the Ras superfamily: Rho GTPases. Rho GTPases, including
RhoA, RhoB, Rac1, Rac2, Cdc42Hs, and TC10, have important roles in membrane
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trafficking, transcriptional regulation, cell growth 37. In particular, FPP interacts with
the Ras protein while GGPP interacts with the Rho protein. Since statins inhibit the
formation of both FPP and GGPP, isoprenylation of Ras and Rho does not happen as
readily, resulting in the inactive form of both building in the cell’s cytoplasm 17.
Inhibition of Rho-GTPases by statins was largely viewed, based on in vitro studies, to be
responsible for their pleiotropic effects. Such effects include: decreasing platelet
activation, anti-thrombotic properties, increasing plaque stability, decreasing vascular
inflammation, decreasing smooth muscle cell hypertrophy and proliferation, decreasing
endothelial dysfunction, and decreasing vasoconstriction 19.

In addition to these pleiotropic effects, statins have other important effects as well. There
are a few mechanisms believed to relate directly to the ability to modulate the immune
system. These effects include modulating the interaction and response of immune cells,
reducing inflammatory cytokines by suppressing their gene expression within the cell,
and antioxidant effects.

Interactions between Statins and Various Immune Cells
Statins have been reported in vitro to bind to and inhibit integrin leukocyte function
antigen-1 (LFA-1) 38, 39. By doing so, LFA-1 is unable to bind to intracellular adhesion
molecule 1 (ICAM-1), which has pathways related to T-cell proliferation among other
important roles in cell signaling and migration. It is important to note that this was
achieved at much higher than clinically prescribed levels 38. Regardless, this has many
researchers wondering about its effect on patients on statin therapy. Statins also interact
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with T-cells by altering their activity. It has been shown in vitro that statins modify Tcell activity directly by inhibiting MHC class II expression induced by interferon gamma
(IFN-γ) 40. In addition, statins have been shown to reduce the inflammatory response of
macrophages and endothelial cells infected with c. pneumoniae mainly through altering
cell signaling in cytokine production 41

Statins, Cytokine Production, and Cellular Signaling
Statins affect several protein kinase cascades because of their ability to decrease levels of
FPP and GGPP. While multiple pathways exist to activate these protein kinases, several
of the Rho and Ras GTPases (e.g. RhoA, Rac1, Cdc42Hs) relate to FPP and GGPP and
are subsequently blocked by statin’s blockage of HMG CoA reductase 42. One important
cascade that is blocked involves nuclear factor-kappa B (NF-κB). NF-κB has an
important role in the production of cytokines in response to lipopolysacchride (LPS) and
bacterial presence. It has been documented that LPS interacts with CD14, causing a
signal transduction via Toll-like receptor-4 (TLR-4), ultimately activating NF-κB 43.
Once NF-κB is activated, it enters the nucleus and produces cytokines that lead to T-cell
maturation and proliferation. NF-κB exists in the cytoplasm, often in its inhibited form
of iκB. When phosphorylated, iκB releases NF-κB and allows NF-κB to travel to the
nucleus to induce the expression of various cytokines, chemokines, and adhesion
molecules. In vitro studies have demonstrated that statins upregulate iκB protein levels,
and therefore reduce the ability of NF-κB to express cytokines 44-46. In addition, statins
inhibit the binding of nuclear proteins to both NFκB and activator protein-1 (AP1) 44.
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The clinical implications of these effects are not known, but could relate to statins impact
on atherosclerosis as well sepsis.

Furthermore, statins have a profound impact on other cellular proteins. Statin treatment
of monocytes in vitro leads to activation of peroxisome proliferator-activated receptor
gamma (PPAR) while inhibiting production of tumor necrosis factor alpha (TNF-α) 47.
PPAR is an important nuclear receptor involved in macrophage function and
development. TNF-α is an important cytokine involved in activation of NF-κB and
MAPK signaling pathways as well as other cytokine production, and even apoptosis.
Statins have also shown to decrease interleukin-1 (IL-1) and interleukin-6 (IL-6) 48. In
addition, there is evidence to support the reduction in levels of monocyte chemoattractant
protein-1 (MCP-1) and interleukin-8 (IL-8) during infection by statin therapy 41. Lastly,
C-reactive protein (CRP), an acute phase reactant, has also been repeatedly demonstrated
to be lower in the presence of statins both in vitro and in vivo 45, 46, 49. By reducing
these levels of cytokines, it is believed that statins may alter the course of sepsis, severe
sepsis, and multiple organ dysfunction syndrome.

Antioxidant effects of Statins
Statins may increase the antioxidant effects of endothelial cells and thus have important
implications in interacting with the immune system. In a study that sought to evaluate the
role of statin treatment on endothelial function, Landemesser et al randomized patients
into a simvastatin and a ezetimibe treatment group for 4 weeks of treatment 50. A variety
of measurements were taken, including endothelium-bound extracellular superoxide
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dismutase (ecSOD). Interestingly, simvastatin improved endothelial function through an
increased ecSOD and reduced vascular oxidative stress, presumed by the reduced impact
the antioxidant vitamin C had on endothelium-dependent vasodilation after simvastatin
50. In addition to an increase in ecSOD, it is felt that statins also increase
hemeoxygenase-1 (HO-1). In a study of rosuvastatin on cultured endothelial cells, free
radial formation was inhibited on the endothelial cells treated with the statin 51. In
addition, rosuvastatin was found to induce HO-1 measured by an increase in mRNA and
protein levels 51. Statins’ anti-inflammatory and anti-oxidant effects, as well as its
ability to lower LDL cholesterol, have direct implications towards its treatment of
endothelial dysfunction, the basis of atherosclerosis.

Atherosclerosis
Elevated serum cholesterol levels play an integral role in the development of
atherosclerosis. Atherosclerosis is an inflammatory “response-to-injury” condition that
affects the medium to large arteries in individuals predisposed to endothelial dysfunction
52. Such endothelial dysfunction is found in association with hypertension, diabetes
mellitus, cigarette smoking, and high serum levels of LDL 52. Atherosclerosis is
initiated by damage to the endothelial layer, often the one-cell thick intima, which leads
to an inflammatory response via the accumulation of monocytes and T-cells that release
various cytokines and chemokines 52. A fatty streak is soon formed, created by foam
cells (monocytes and macrophages filled with lipid) as the disease progresses 52-54. In
advanced disease, a fibrous cap, formed by various growth factors, covers the lesion
filled with leukocytes, LDL cholesterol, and other components of the fatty streak 52-54.
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In time, the fibrous plaque may ulcerate or rupture, and leads to thrombus formation
and/or complete occlusion of the artery from platelet aggregation, leading to ischemia 52.
Clinically, this is seen as coronary artery disease (CAD) and myocardial infarctions (MI),
cerebral vascular disease and stroke, and peripheral vascular disease and ischemic limb.

Statin Clinical Trials and Lipid Lowering Properties
Decreasing circulating serum cholesterol has long been both a treatment and a prevention
strategy for improving health, particularly for preventing CAD. The Framingham Study
made famous the relationship between serum cholesterol, risk of CHD, and premature
death from CHD 55-57. In 1984, the Lipid Research Clinic Coronary Primary Prevention
Trial (LRC-CPPT) concluded that a reduction in the total cholesterol level (via lowering
LDL cholesterol) diminished the incidence of coronary heart disease (CHD) morbidity
and mortality in patients 35, 58. The LRC-CPPT was a large, multi-center, randomized,
double blind study that included 3,806 asymptomatic, middle-aged men with primary
hypercholesterolemia 58. The study had two treatment arms, cholestryamine versus
placebo, and used CHD, death, or non-fatal myocardial infarction (MI) as primary
endpoints. In cholestryamine-treated group, a 19% reduction in risk (p < 0.05) was found
that corresponded with a decrease in the patient’s plasma total and LDL cholesterol levels
35. The study concluded that the lipid lowering benefits of the cholestryamine aided in
this reduction of risk.

In the POSCH or the Program on the Surgical Control of the Hyperlipidemias in 1990,
surgeons performed partial ileal bypass procedures on patients in an attempt to lower
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cholesterol 59. The study, a randomized clinical trial featuring 838 patients who had
evidence of CHD (through documented prior MI), showed a decrease in LDL, increase in
high-density lipoprotein (HDL) cholesterol, and overall reduction in morbidity and
mortality from CHD 59. The study concluded that while partial ileal bypass needed to be
studied more, there was strong evidence to support lipid modification in the reduction of
morbidity and mortality of CHD 59. The measurement of circulating serum cholesterol
levels was the focus of the National Cholesterol Education Program as a high-risk
intervention strategy to combat hypercholesterolemia and reduce the risk of CAD 36, 60,
61. The mounting research yielded the Lipid Hypothesis, which suggested that by
decreasing serum cholesterol, one could expect a reduction in risk of developing CHD.
Lipid lowering medications, including statins, were therefore studied extensively for their
direct role of inhibiting cholesterol biosynthesis and reducing circulating serum
cholesterol in patients at risk for developing CAD.

Several clinical trials have studied the role of statins in cardiovascular disease 33, 34, 6266. These trials often demonstrate the beneficial effects that statins have on lowering
serum cholesterol and reducing risk of CHD. In the Scandinavian Simvastatin Survival
Study (4S), a double-blind randomized-controlled trial (simvastatin versus placebo)
featuring 4,444 patients with CHD, simvastatin decreased total cholesterol and LDL
cholesterol by 25% and 35% respectively 62. In addition, the study showed that there
was a slightly greater 6-year probability of survival (87.6% for placebo versus 91.3% for
simvastatin) making simvastin safe for long-term use and beneficial in patients with CHD
62.
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In 1996, the Cholesterol and Recurrent Events Trial (CARE) investigators published a
study that examined the role of pravastatin on coronary events in patients with previous
history of MI. The study was a 5-year double-blind randomized controlled trial with a
total of 4,159 patients and found that statins were a benefit to patients with underlying
CAD who had average cholesterol levels. The study found a 24% risk reduction between
the pravastatin group and the placebo group 63. Likewise, the Long-Term Intervention
with Pravastatin in Ischemic Disease (LIPID) Study Group performed a double-blind,
randomized controlled trial comparing the effects of pravastatin versus placebo. The
9,014 patients ranged in age from 31 to 75 years, had documented CHD (either history of
myocardial infarction or unstable angina), and total serum cholesterol between 155 to 271
mg per deciliter 34. In these patients, pravastatin reduced the risk of MI, stroke, coronary
revascularization, mortality from CHD, and overall mortality 34. These studies provided
sufficient evidence to support the use of statins to safely reduce serum cholesterol levels
for the treatment of CHD with the Lipid Hypothesis the basis of statin therapy.

Evidence of Statins Beyond Lipid Lowering
The lipid lowering benefits of statins were demonstrated in vivo in the 4S, CARE, and
LIPID trials. However, the only evidence of the pleiotropic mechanisms of statins was in
vitro; it was hard to extrapolate these in vitro results to determine a plausible effect in
vivo. Two very important studies noted the pleiotropic effects of statin therapy. They
gave credence to a realistic possibility of a clinically apparent alternative mechanism of
statin therapy. The first was the West of Scotland Coronary Prevention (WOSCOP). The
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WOSCOP, whose primary aim was to demonstrate the ability of pravastatin to reduce
morbidity and mortality from CHD in men who had moderate hypercholesterolemia,
showed that several patients benefited from treatment beyond LDL reduction 33. The
study compared the pravastatin versus placebo groups and used a Cox regression model
to examine baseline lipid levels, treatment lipid levels, cardiovascular events, and
subsequent risk reduction in those receiving pravastatin. In the analysis, there was a
benefit (noted by a lower CHD risk) of pravastatin over placebo found in a quintile of the
patients with the same LDL level, resulting in the conclusion that LDL reduction alone
could not account for the benefit 33. It was felt that there were benefits to the pravastatin
beyond decreasing serum LDL. Similarly, the previously mentioned CARE study showed
a sub-group analysis that alluded to the benefits of statins in patients where serum
cholesterol reduction could not account for the benefit. In this study, it was found that
when pravastatin and placebo groups with similar serum cholesterol levels were
compared, the pravastatin group had significantly lower risk of CHD 63. Again, a
decrease in serum cholesterol alone could not account for the improved benefit.

In both the WOSCOP and CARE studies, sub-group analysis demonstrated a benefit to
statin therapy in the absence of significant reduction of serum cholesterol. These
cholesterol-independent effects have also come to light when comparing the amount of
time it takes for a treatment to have a benefit. In two non-statin in vivo studies, the
POSCH and the LRC-CPPT, it took greater than 7 years for a benefit of treatment
whereas it takes around 5 years in the statin groups 17, 35, 59. In fact, the Pravastatin or
Atorvastatin Evaluation and Infection Therapy – Thrombolysis in Myocardial Infarction

16
22 or PROVE-IT TIMI 22, researchers observed a benefit of both standard therapy (40
mg pravastatin) and intensive therapy (80 mg atorvastatin) in patients presenting with
acute coronary syndrome when treatment was started within 10 days of hospitalization
67. Furthermore, statin trials have a greater overall cardiovascular benefit compared to
the non-statin trials 17.

Other trials have also alluded to the dramatic benefit of statins outside of their ability to
lower serum cholesterol. One small study sought to compare simvasatin with ezetimibe,
a cholesterol absorption inhibitor in 20 patients with chronic heart failure 50. The
researchers hypothesized that both simvastatin and ezetimibe would lower LDL
cholesterol, but have differing effects on endothelial function over a 4 week period 50.
The study found that simvastatin improved endothelial function when compared to
ezetimibe even though both simvastatin and ezetimibe had similar reduction in LDL
cholesterol 50. A similar study also compared atorvastatin and ezetimibe in a group of
patients with stable CAD, finding similar results in comparable reduction in LDL
cholesterol but improved endothelial function in atorvastatin 68. The evidence from
these trials and in vivo studies joined the mounting evidence from in vitro studies on the
pleiotropic effects of statins.

Statins and Infections
With knowledge and clear evidence of the pleiotropic effects of statins in cardiovascular
disease, several researchers decided to test the hypothesis of statins’ abilities to affect the
immune system. Therefore, several in vivo studies have looked at the role of statins in
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patients with sepsis 21, 27, 69-72. The largest of these studies was performed in Canada,
taking advantage of the administrative records and universal coverage. Hackam et al
performed a 5-year population-based cohort analysis on nearly 69,168 patients with
cardiovascular disease that had been hospitalized for acute coronary syndrome, stroke, or
revascularization that had survived at least 90 days after discharge 70. Half of the patients
received a statin (34,584) while the other half did not. The study showed that the
incidence of sepsis was lower in patients receiving statins, at roughly 71.2 events per
10,000 person-years for the statin group versus 88.0 events per 10,000 person-years for
patients not receiving statins (p=0.00003) 70. This equated to univariate hazard ratio
(HR) of 0.81 (95% CI of 0.72 – 0.91) and a multivariate (adjusted for demographics, risk
factors for sepsis, and other co-morbidities) HR of 0.81 (95% confidence interval of 0.72
– 0.90) 70. The study also found further evidence that those patients receiving statins also
had a decreased incident of fatal sepsis 70.

In 2001, Liappis et al studied the impact of statins on mortality of patients with bactermia
in the mostly male population of their VAMC. In this retrospective review of 388
infections secondary to aerobic gram-negative bacilli and staphylococcus aureus, the
investigators found an overall hospital mortality rate of 6% in patients receiving statins
compared to 28% for patients not receiving statins (P = 0.002) 69. The study found an
attributable morality rate of 3% for patients on statins compared to 20% for patients not
receiving statins (p = 0.010) 69. Conclusions about the effects of specific statins were not
possible because of the low numbers of patients. The study proposed that a statin’s
beneficial effect on patients with bactermia was the ability to interrupt the
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proinflammatory cytokine release related to infection. However, with such low numbers
of patients, even though they are statistically significant, it may be difficult to draw major
conclusions about the use of statins in patients with infections.

Almong et al performed a prospective observational cohort study, published in 2004,
exploring the relationship between statins and sepsis. In this study, it was hypothesized
that preadmission statin use will have protective effects against severe sepsis and
therefore patients receiving statins would develop sepsis less frequently than those not
receiving statin therapy 21. Patients greater than 40 years old, non-pregnant, without HIV
or malignancy, and on statin therapy for greater than one month admitted to the ICU with
documented acute bacterial infection were enrolled prospectively. The acute bacterial
infections included pneumonia, urinary tract infection, and cellulitis. The study used the
definition of severe sepsis and sepsis-induced organ dysfunction set forth by the Protein
C Worldwide Evaluation in Severe Sepsis (PROWESS) investigators 21. Ultimately, 361
patients were included in the study, 82 patients in the statin group versus 279 patients in
the non-statin group 21. One hundred and seventy seven patients or 49% of the patients
admitted to the ICU were diagnosed with pneumonia, 38.8% had urinary tract infection,
and 12.2% had cellulitis 21. The study found that the rate of severe sepsis in the group
not receiving statins was 19% (95% CI 14.4% to 23.6%), whereas the rate in the statin
group was 2.4% (95% CI 0% to 5.7%) 21. There was also a decreased 28 day mortality
rate for the patients receiving statins (3.7% versus 8.6%) (p = 0.14). A logistic regression
analysis was also performed to adjust for variables identified in the univariate analysis to
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be associated with severe sepsis. Results showed that statin treatment, serum albumin,
and APACHE II score, were all associated with a reduction in severe sepsis 21.

Mortensen et al performed a retrospective study to explore the role of pre-admission
statin use on 30 day mortality for patients hospitalized for pneumonia 27. The study took
place at two academic tertiary care hospitals and included patients admitted with
pneumonia, evident by both chest x-ray and by ICD-9 diagnosis of pneumonia on
discharge. A pneumonia severity index score was calculated for each of the patients
(based on demographic, co-morbid illness, physical examination findings, and laboratory
and radiographic findings). Data were included from 787 patients, of which 52% were
low risk (pneumonia severity index class between I and III) 34% were moderate risk,
(pneumonia severity index class of IV) and 14% were high risk (pneumonia severity
index class of V) 27. Of the enrolled patients, 110 were on statins. The 30 day and 90
mortality rates were 9.2% and 13.6% respectively. In univariate analysis several
components of the pneumonia severity index were statistically associated with 30
mortality, including demographics (age and nursing home residency), past medical
history (heart failure, stroke, malignancy, diabetes,) and clinical parameters (blood
pressure, elevated glucose). In multivariable regression analysis, statin use was found to
decrease the 30 day morality rate, with an AOR 0.36 (95% CI 0.14-0.92) 27.

In a similar study done prospectively, Chalmers et al studied the role of statins in patients
with community-acquired pneumonia. This prospective observational study sought to
characterize the effects of other medications the enrolled patients were taking, by
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collecting information about ACE inhibitors, beta-blockers, and aspirin as well as statin
24. This was the first study designed to elucidate the effects of other cardiovascular
medications with statins on 30 day mortality rate and incidence of pneumonia. The
outcomes in this study were 30 day mortality, mechanical ventilation or pharmacologic
(inotropic) support, and progression of disease to a more complicated pneumonia, such as
effusion or empyema. Laboratory data, including C-reactive protein levels were
collected and a pneumonia severity index (PSI) was calculated for each patient. In all,
1007 patients with community-acquired pneumonia were enrolled. Multivariate logistic
regression revealed that statin therapy was associated with a reduced 30 day mortality
(AOR 0.46; 95% CI 0.25 – 0.85, p = 0.01) 24. Age over six five years old, pneumonia
severity greater than or equal to 4, chronic cardiac failure, and beta-blocker use were all
associated with increased 30-day mortality. Statin use was also associated with a reduced
incidence of complications from pneumonia (AOR 0.44; 95% CI 0.25 – 0.79, p = 0.006),
while PSI greater than or equal to 4 was indicative of increased risk of developing a
complication (AOR 1.49; 95% CI 1.16 – 1.83, p = 0.001) 24. Although statin users
tended to have the highest PSI compared to patients not prescribed any cardiovascular
medications, admission C-reactive protein levels were significantly lower for patients
receiving statins compared to patients receiving other cardiovascular medications and to
patients not receiving any cardiovascular medications. C-Reactive protein levels at day
four for patients receiving statins tended to be lower as well. The study concluded that
there was no benefit from aspirin, ACE inhibitors, or angiotensin II receptor antagonists
in patients admitted for the treatment of community-acquired pneumonia. C-reactive
protein levels were reduced in patients treated with statins, confirming a reduction in
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systemic inflammation through statin treatment. Lastly, a reduction in 30 day mortality
and complicated pneumonia was seen in association with statin use.

In a similar study from Denmark, Thomsen et al conducted a population-based cohort
study of 29,900 adults hospitalized with pneumonia over a seven-year period. These
investigators sought to study the association between preadmission use of statins in
patients hospitalized for pneumonia, the risk of nosocomial bacteremia and pneumonia
complications, and the 30 and 90 day mortality 73. Current statin users were identified as
any patient that filled at least one prescription within 125 days of admission (chosen
because of a compliance rate of 80% to 100% in the Danish patient population). Those
with at least one prescription filled prior to 125 days of admission were grouped as
former statin users. Other demographic and clinical data were also extracted from the
hospital database, including age, sex, co-morbidities, concurrent medication usage, and
severity of pneumonia (based on the Charlson Comorbidity Index score) 73. The primary
outcome measure was death (any cause) within 30 days and 90 days after admission, with
secondary outcomes being bacteremia and pulmonary complications, namely pleural
effusion, lung abscess, empyema, or adult respiratory distress syndrome (ARDS). In the
final analysis, statin users were more likely to be older, have more co-morbidities (2-5
times likely to have had a MI, heart failure, vascular disease, or diabetes) and therefore
on average have higher co-morbidity index scores. Yet, the 30-day mortality rate for
statin users was 10.3%, compared to 15.7% for non-statin users (the crude mortality RR
was 0.63; 95% CI 0.54 – 0.75, p < 0.01) 73. Likewise, the 90-day mortality rate for the
statin users was also lower than the non-statin users at 16.8% compared to 22.4% (the
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crude morality RR was 0.72; 95% CI 0.63 – 0.82, p < 0.01) 73. The study found no
association between mortality and preadmission use of ACE inhibitors or low-dose
aspirin, but a slight decreased mortality was found in association with beta-blockers. The
cumulative incidence of pulmonary complications was 1.5% for statin users and 2.1% of
non-statin users. This yielded a slight reduction in the risk of pulmonary complications,
although it was not statistically significant with an adjusted RR of 0.69 (95% CI 0.42 –
1.14) 73.

Another retrospective study, performed by Martin et al, explored the association between
statins, severe sepsis, and organ dysfunction amongst patients with severe sepsis 74.
Using data from patients admitted over a 1 year time period, the study used admission
ICD-9 codes for septicemia, unspecified septicemia, systemic inflammatory response
syndrome with and without organ dysfunction for inclusion criteria. Pharmacy records
and admission history and physical examination results from the patient’s electronic
medical records were used to confirm if the patients were taking statins before and during
admission. Exclusion criteria included age younger than 40 years, transfer during
medical care from another institution, statins use during admission but not before,
malignancy, HIV positive status, neutropenia, and immunosuppressant drug treatment.
The primary endpoint was severe sepsis, defined by the American College of Chest
Physicians and the Society of Critical Care Medicine (ACCP-SCCM) as sepsis with at
least one organ dysfunction such as cardiovascular, renal, pulmonary, hematologic, or
metabolic. The secondary end points were 30 day in-hospital mortality rate and the rates
of cardiovascular, renal, pulmonary, hematologic, and metabolic organ dysfunction. In
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the end, only 53 patients met all eligibility criteria, 16 in the statin group and 37 in the
non-statin group. The rate of severe sepsis in the statin group was 56% compared to a
rate of 86% in the non-statin group, showing that statins were associated with a 30%
reduction in the rate of severe sepsis 74. There was also a statistically significant
difference in the in-hospital mortality rate, with the statin group having a rate of 38% and
the non-statin group having a rate of 49% (p = 0.33). In sub-group analysis, the rate of
cardiovascular dysfunction was significantly lower in the statin group versus the nonstatin group (38% versus 73%, p <0.02) 74. The study concluded that statins’ ability to
maintain vascular integrity was responsible for the differences in rates of cardiovascular
dysfunction. While the difference in mortality rate among statin users and non-users was
not significant, the authors attributed this finding to the small sample size.

Kruger et al. conducted a retrospective cohort analysis to find the association between
statins and deaths due to bacteremia. Data were collected on 438 patients over age 18
years old that were admitted for bacteremia over a four-year period 72. Clinical and
demographic information included: age, ICU admission, co-morbidities (hypertension,
diabetes, heart failure,) and medications (ACE inhibitors, aspirin, beta-blockers).
Baseline characteristics associated with hospital mortality from bacteremia were
identified and included age, immunosuppression, and e. coli infection. Sixty-six patients
were receiving statins prior to admission while 372 patients did not receive statins; 10
patients stopped statin therapy after being admitted, while 56 continue statin therapy.
Results showed that statins were associated with reduced hospital mortality, with an OR
of 0.39 (95% CI 0.17 – 0.91, p = 0.029) 72. Deaths attributable to bacteremia were also
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reduced in patients on preadmission statins that continued therapy throughout
hospitalization (OR 0.29; 95% CI 0.10 – 0.86, p = 0.025) 72. Likewise, it was also
associated with reduced mortality (OR of 0.06; 95% CI 0.01 – 0.44, p = 0.0056) 72.
Mortality rates were highest in patients who did not have preadmission statins during the
hospital stay.

In an effort to further characterize the effect of statins and their ability to reduce
inflammation, Schmidt et al performed a retrospective cohort study evaluating the impact
of statins in patients with multiple organ dysfunction syndrome (MODS) 75. The
hypothesis, predicated on the ability of statins to reduce incidence of sepsis and
septicemia, was that preadmission statin treatment would have a survival benefit for
MODS patients. In all, 40 MODS patients using statins were age and sex matched with
80 MODS patients not receiving statins. Inclusion criteria for the patients in the study
were admission to ICU and APACHE II score greater than or equal to 20 at admission.
There was no difference in baseline characteristics (age, APACHE II, Sequential Organ
Failure Assessment or SOFA) between the groups. In the end, the 28 day mortality rate
was 33% for the statin treated group compared to 53% for the non-statin group. A Cox
proportional hazard analysis showed a HR of 0.53 (95% CI 0.29 to 0.99, p = 0.04) 75.
The study concluded that statin therapy decreases 28 day mortality rate for MODS
patients with equally severe disease.

Statins and the Surgical Patient
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Studies have shown beneficial effects of preoperative statins use on the reduction of
morbidity and mortality of cardiac and vascular surgery patients postoperatively 20, 7685. Recently, two meta-analysis studies have attempted to consolidate the findings for
cardiac, vascular, and non-cardiac surgery 86, 87. Hindler et al performed a metaanalysis of the studies exploring the role of preoperative statin use and postoperative
outcomes. The study conducted a thorough literature review of MEDLINE, EMBASE,
the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systemic
Reviews, the American College of Physicians Journal Club, and the Database of
Abstracts of Reviews of Effects (as well as several abstracts from conferences and
scientific meetings), to identify randomized, prospective clinical trial and retrospective
observational studies published from 1977 to 2005 on the topic 87. Publications that
detailed preoperative statin use and surgical outcomes were included. Outcomes
included, MI, cardiac arrhythmia, stroke, and 30-day mortality. Each qualified study was
placed into one of three groups: cardiac, vascular, or non-cardiovascular surgery. The
quality of each study was then evaluated and rated based on randomization of
participants, randomization of procedures, control group, and monitoring treatment
fidelity. Of the 1,100 abstracts evaluated, there were 15 total publications that met all
inclusion criteria: seven articles about cardiac surgery and statins, seven articles about
vascular surgery and statins, and one article for non-cardiac surgery.

In the meta-analysis, the study found that postoperative mortality was significantly lower
in patients receiving statins (1.9% versus 3.1%, p < 0.0001 for n = 12,752 in 7 studies)
87. Interestingly, there was an increase in the incidence of MI in those patients receiving
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statins (4.6% versus 3.6%, p = 0.02 for n = 7,615 in 5 studies) 87. There was no
significant difference between the two groups for cardiac arrhythmia or stroke (22.3%
versus 23.0%, p = 0.99 for n = 3,294 in 3 studies and 2.7% versus 3.2%, p = 0.26 for n =
4,872 in 3 studies, respectively) 87.

The meta-analysis for patients undergoing vascular surgery yielded comparable results
for mortality and cardiac arrhythmia, but not for MI and stroke. Postoperative mortality
was reduced in patients receiving statins (1.7% versus 6.1%, p < 0.0001 for n = 5,373 in
7 studies) 87. Unlike the cardiac surgery meta-analysis, statin use was associated with a
reduction in the incidence of MI (2.7% versus 6.2%, p = 0.001 for n = 2,862 in 5 studies)
and stroke (2.0% versus 3.3%, p = 0.049 for n = 2,749 in 4 studies) in vascular surgery
patients 87. There was no significant difference in the rate of cardiac arrhythmia
amongst vascular surgery patients receiving statins (11.4% versus 11.1%, p = 1.0 for n =
329 in 2 studies) 87.

When evaluating all types of surgical procedures (which included cardiac, vascular, and
thoracic surgeries), the researchers found a 1.0% absolute reduction of 30 day
postoperative mortality for statin users (2.2% versus 3.2%, p < 0.0001) 87. They also
found a 44% reduction in the odds of 30 day mortality in patients undergoing surgical
procedures on statin therapy (OR 0.56; 95% CI 0.43 – 0.71). The compilation of this data
demonstrates the cumulative evidence of statins and their association of reducing the 30
day mortality after cardiac, vascular, and thoracic surgery. While there were flaws and
weaknesses to this study, including varying methodologies in the analyzed studies, the
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inclusion of mostly retrospective observational studies, the weight of a few large studies
possibly skewing the data, and an inability to control for confounders, the study
concluded that statins were associated with a survival benefit in surgical patients.

The other meta-analysis, performed by Liakopoulos et al, focused on the magnitude of
cardiac surgery studies and their relationship with preoperative statin use. MEDLINE,
EMBASE and the Cochrane Library (including the Cochrane Database of Systemic
Reviews, Database of Abstracts of Reviews and Effects, and The Cochrane Central
Register of Controlled Trials) as well as abstracts and oral presentations from several
scientific meetings for retrospective observational studies and RCT were searched 86.
The study extracted information on 30 day mortality, MI, atrial fibrillation, stroke, and
renal failure. Each publication was evaluated for their quality, clinical outcomes, and
type of surgery performed. In total, 31,201 cardiac surgery patients were included from
19 publications from 1999 to 2007 (3 were RCT, 3 were prospective observational, and
13 were retrospective observational) 86. Seventeen thousand, two hundred and one
patients were on preoperative statin therapy, with the remaining 14,524 not on statins.

The meta-analysis showed a reduced incidence of short-term mortality in cardiac surgery
patients receiving statins before cardiac surgery compared to patients not receiving statins
(2.2% versus 3.7%, p < 0.0001), with an absolute risk reduction of 1.5% (from 15 studies
with an n = 28,517) 86. This equated to an OR of 0.57 (95% CI 0.49 – 0.67, p < 0.0001),
or a 43% reduction in the risk of 30 day mortality in patients receiving statins. However,
no significant difference was found in the reduction in incidence of MI between the two
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groups (4.2% versus 3.9%, p = 0.373 from 10 studies with an n = 14,330) 86. This was
equivalent to an OR of 1.11 (95% CI 0.93 – 1.33, p = 0.25). In 7 studies with 7,643
patients there was an overall incidence rate of 26.9% for postoperative atrial fibrillation,
with patients receiving statins having an incidence rate of 24.9% compared to the nonstatin group with an incidence rate of 29.2% (p < 0.0001) 86. This was the equivalent of
a 4.3% absolute risk reduction and a 33% reduction in the odds of atrial fibrillation for
patients receiving statins (with an OR of 0.67; 95% CI 0.51 – 0.88, p = 0.004). Likewise,
the study found a lower rate of stroke (2.1% versus 2.9%, p = 0.001) in patients on statin
therapy 86. This was equivalent to a 26% reduction in the odds of stroke for cardiac
surgery patients receiving statins before surgery (OR 0.74; 95% CI 0.60 – 0.91, p = 0.004
from 7 studies with an n = 16,390). Lastly, the study did not find a statistically
significant reduction of the incident of renal failure. Among the 5 studies analyzed (with
a total of 6,408 patients), the incidence of renal failure amongst statins and non-statin
patients was 3.9% and 4.5% respectively (p = 0.275), with the OR being 0.78 (95% CI
0.46 – 1.31, p = 0.34). Since it was not statistically significant, the study did not believe
that the evidence was sufficient to suggest statins protect against renal failure 86.
However, this was in contradiction to other studies that have shown renal protective
effects of statins 85.

From these meta-analyses, there was clear evidence of the association between statins
and a reduced risk of all cause short-term mortality and a decreased incidence and risk of
cardiovascular postoperative. Both the Hindler and the Liakopoulos studies found
reduction in absolute risk of all cause short-term mortality. In particular, the Hindler
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study was able to demonstrate the effect of statins in both cardiac and non-cardiac
surgeries, including vascular surgery and thoracic surgery.

Statins and Surgical Infections
Only one study has looked at preoperative statin use and postoperative infectious
complications 82. Coleman et al performed a retrospective observational study on
patients undergoing coronary artery bypass surgery (CABG), cardiac valve surgery, or
both. Postoperative infectious complications that were followed included: pneumonia,
bacteremia, urinary tract infection, leg vein harvest site infection, tracheotomy site
infection, prolonged length of stay, and death. The primary endpoint was the combined
incidence of any infectious outcome, while secondary endpoints were the incidence of
individual infectious complications, death, and prolonged hospitalization (greater than 6
days). Looking back on records from January 2004 through August 2006, the researchers
identified 1,934 patients that were eligible to be enrolled in their analysis, of which 1,248
patients received preadmission statins while 686 did not receive any statin therapy. There
were some variations between the statin therapy patients and the non-statin therapy
patients with respect to demographic, preoperative, and perioperative variables. For
example, statin users were more likely to have a history of diabetes, chronic obstructive
pulmonary disease high cholesterol, and to be smokers than patients not on preoperative
statin therapy.

The researchers found that a total of 151 patients developed at least one postoperative
infectious complication. Using a multivariable logistic regression to control for potential
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confounders in the preoperative and perioperative variables, a 33% reduction in the risk
of developing a postoperative infectious complication of any kind (AOR 0.67; 95% CI
0.46 – 0.99, p = 0.04 for n = 151) was found. Evaluation specific sub-groups, showed a
trend towards improvement with statin use for all other endpoints: pneumonia 33%
reduction (AOR of 0.67; 95% CI 0.43 – 1.04, p = 0.08), bacteremia 29% reduction in risk
(AOR of 0.71; 95% CI 0.32 – 1.39, p = 0.40), urinary tract infection 35% reduction
(AOR of 0.65; 95% CI 0.31 – 1.39, p = 0.27), and leg vein harvest site infection risk was
reduced by 1% (AOR 0.99; 95% CI 0.30 – 3.26, p = 0.99). Oddly, the study found that
deep sternal wound infection risk was increased by 20% (AOR of 1.20; 95% CI 0.44 –
3.25, p = 0.72). There was also an association (but not statistically significant) of reduced
risk of death with an AOR of 0.85 (95% CI 0.51 – 1.43, p = 0.54) and a statistically
significant reduction in length of stay (AOR 0.80; 95% CI 0.64 – 0.99, p = 0.04). Several
independent predictors of infection were identified, including: history of diabetes, COPD,
morbid obesity, valve surgery, longer perfusion time during the operation, and red blood
cell use during the operation.

In the current study, we expand on the previously outlined hypotheses on the pleiotropic
effects of statins on inflammation, sepsis, and 30 day mortality in medicine and surgical
patients and apply it to non-cardiac and vascular surgical patients.
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Section 5: Statement of Purpose
The purpose of this study is to determine the role preoperative statin therapy has on
postoperative infectious complications and 30 day postoperative mortality in general and
non-cardiac surgical patients.

Specific Hypothesis
We believe that general and vascular surgery patients receiving statins prior to admission
will have a reduced risk of postoperative infections and reduce 30 day postoperative
mortality.

Specific Aims Of The Thesis
The primary outcome measure will be the development of any postoperative infectious
complication. Postoperative infectious complications will include sepsis, septic shock,
pneumonia, urinary tract infection, surgical site infection, deep surgical site infection, and
wound disruption. Secondary outcomes include incidence of each of the postoperative
infectious complications and 30 day mortality. We will also perform a multivariable
logistic regression to account for factors that may confound the effect of statins. We hope
to demonstrate that statins reduce postoperative infectious complication in general
surgery and vascular surgery patients and reduce the risk of 30-day morality.
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Section 6: Methods
Study Design
The approach and methods of the American College of Surgeons National Surgical
Quality Improvement Program have been previously described in detail 88-92. Between
1991 and 1993, the National Veterans Affairs Surgical Risk Study (NVASRS) was
conducted at 44 VA Medical Centers (VAMCs) to develop and validate risk-adjustment
models for predicting surgical outcomes 93. This study was undertaken in response to a
Congressional law passed in 1986 that required VAMCs to report operative mortality
rates and compare them to the national average. Since there was not a consensus on
national operative mortality rates for various surgical disciplines, the NVASRS was
created. Ultimately, this effort was accomplished to improve the delivery of surgical care
at all VAMCs and to comply with the congressional mandate.
Trained surgical nurses collected and entered data for each participating VAMC in order
to be certain information on preoperative, perioperative, and 30-day outcomes was
standardized. Each outcome variable was clearly defined. These data were then
submitted to a central data analysis center and risk-adjusted models of general surgical
outcomes were created and validated. These risk-adjusted models were then expanded to
include vascular surgery, orthopaedics, urology, thoracic (non-cardiac), and several other
disciplines 90. The goal was to be able to appropriately monitor and evaluate the quality
of the surgical care at all VAMCs and have the ability to make necessary changes to
improve performance.
The VA National Surgical Quality Improvement Program (VA NSQIP), which started in
1994, is an extension of the initial NVASRS. It allowed participating VAMCs to be able
to continue to report on operative mortality rates while making improvements based on
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the information they collected. In 2004, the model was adopted by the American College
of Surgeons (ACS) and disseminated to a variety of non-VA hospitals.
In both the VA and the ACS NSQIP programs, data collected by the NSQIP nurses
include total number of procedures by surgical specialty, inpatient or outpatient status,
and major or minor status (based on specific type of procedure and type of anesthesia
used) 90. In addition risk-adjustment data is collected which includes 45 pre-surgical, 17
surgical, and 33 outcomes variables 90. These data are entered into each institution’s
local database and are submitted to national data processing center to create the risk
adjusted models. Thirty days mortality and morbidity are reported as observed to
expected ratios. The ACS NSQIP has been verified as a consistent and accurate source of
data on surgical outcomes.
The present study is a retrospective review of the ACS NSQIP data from the Brigham
and Women’s Hospital (BWH), a 777-bed hospital affiliated with Harvard Medical
School (HMS) from January 1, 2006 to January 1, 2008. We received approval from the
Human Subjects Office at our institution prior to the start of the study. Pharmacy data
from the BWH pharmacy database were extracted for the same time period and the
patient medical record number (MRN) was matched with the ACS NSQIP MRN for the
same time period. If the patient was receiving a statin preoperatively, it was noted and
recorded, and confirmed with inpatient statin records.

Study Population
The study population included all non-cardiac, general and vascular surgery patients
above the age of 18 admitted to the inpatient surgical floor. Patients included men and
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women of any race who were admitted for emergent and non-emergent procedures.
Excluded were patients under age 18, those undergoing cardiac surgery, and those
undergoing outpatient surgical procedures.

Data Collection
As per the ACS NSQIP protocol, trained surgical clinical nurses prospectively input a
series of objective variables for operative morbidity and morality risk into the BWH local
NSQIP. Included in the data entry were presurgical characteristics (age, race, presurgical
WBC, American Society of Anesthesiology classification or ASA, diabetic status on
insulin or oral therapy, steroid therapy, type of case, and urgency of case), perioperative
characteristics (use of intraoperative RBC, length of operation), and postoperative
characteristics (length of hospital stay, occurrence of postoperative infectious
complications, and 30 day postoperative mortality). Postoperative infectious
complications (POIC) included sepsis, septic shock, pneumonia (PNA), urinary tract
infection (UTI), surgical site infection (SSI), deep surgical site infection (DSSI), or
wound disruption (WD). The ACS NSQIP, for standardized collection purposes, defined
POIC for all institutions that participate, based on guidelines from the Center for Disease
Control and Prevention (CDC) 93. ASA, a powerful predictor of surgical risk, was
determined by placing the patient into one of five categories based on the patient’s health
status (ASA 6, a moribund patient under-going organ procurement, was not applicable in
this study). In analysis, ASA 4 and ASA 5 classifications were combined into one
classification (noted as ASA 4-5). ASA 1 is reserved for a patient who is healthy, ASA 2
for a patient with mild systemic disease, ASA 3 for a severe systemic disease, ASA 4 for
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a patient with a life-threatening systemic disease, and ASA 5 for a patient not expected to
survive greater than 24 hours without surgery 97,98. Pharmacy data from the hospital’s
electronic computerized physician order entry and pharmacy database was extracted by a
pharmacist at BWH and placed in an excel file. This list contained information on
whether or not the patient was receiving and statin, and if so, the type of statin and
dosage. This file, which included the patient’s MRN and date of admission, was then
merged with the BWH ACS NSQIP database for the similar time period and matched by
MRN.

Outcome Measures
The primary outcome measure was the combined occurrence of any postoperative
infectious complication (POIC). Secondary outcome measures included 30 day
postoperative mortality, individual POIC, and length of hospital stay.

Statistical Analysis
The BWH ACS NSQIP and pharmacy records were merged and sorted on an excel sheet
by MRN. SAS statistical software, version 9.1 (SAS Institute Inc, Cary, North Carolina)
was used to perform all analyses of the data. A Wilcoxon rank sum test was performed
for comparing continuous variables in the dataset. Fisher exact test was performed to
determine differences in proportions between two groups for dichotomous and
categorical variables. Multivariate logistic regression was used to determine if statins
were an important predictor for dichotomous outcome.
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Section 7: Results
Demographic and Clinical Data of Patients Receiving Statins
A total of 2,584 patients met the criteria of the study and were included in analysis. Of
these, 578 were on statin therapy at the time of admission and subsequently received
statin therapy on the surgical floor. The characteristics of the patients are featured in
Table 1. Patients receiving statins tended to be older (66.5 ± 11.5 years versus 51.75 ±
15.6 years, p<0.0001), were less likely to undergo a general surgery procedure (58% of
patients with statins underwent general surgery procedures versus 95% of the non-statin
group, p <0.001), have greater surgical risk determined through ASA, were more likely to
be diabetic (27% of statin patients versus 9% of the non-statin patients), were more likely
to be receiving steroids (5.5% of statin patients received steroids versus 2.7% of the nonstatin group, p = 0.039). Intraoperatively, patients on statins tended to receive more units
of RBC (8% of statin patients received >2 units of RBC versus 2% of the non-statin
group, p = 0.00025) and have longer operations (statin group had a mean length of
operation of 2.68 ± 1.8 hours versus a mean length of operation of 2.38 ± 1.4 hours for
the non-statin group, p = 0.006). Postoperatively, statin patients tended to have a longer
hospital length of stay (statin patients had a mean stay of 7.8 days versus 5.5 days for the
non-statin group). There was no significant association between race, urgency of the
case, or preoperative WBC.
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TABLE 1: Demographic and Clinical Characteristics of Patients Receiving Statins
Demographic and Clinical Data by Statin
Statin Group
Non-statin Group
Age ± mean SD (yr)
n

p value

66.5 ± 11.5
578

51.75 ± 15.6
2006

48 (9%)
5 (1%)
479 (90%)

168 (9.3%)
30 (1.6%)
1598 (88.9%)

General Surgery
Procedure
yes
no

136
98

726
36

<0.0001

Emergent
yes
no

61
507

186
1805

0.319

ASA
1
2
3
4-5

2
86
136
10

74
476
205
7

<0.0001

Diabetes
insulin
oral
no

33
31
170

26
42
694

<0.0001

Steroids
yes
no

13
221

741
21

0.039

8.99
310

8.42
1039

215
19

741
21

0.00025

2.68 ± 1.8
569

2.38 ± 1.4
1991

0.006

7.81
576

5.52
1994

<0.0001

Race
Black
Other
White

Preoperative WBC
(103/mm3)
n
Units of RBC
0-2 units
>2 units
Length of Operation (hr)
n
Length of Stay (days)
n

<0.0001
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Demographic and Clinical Data, Infectious Complication
There were a total of 224 POIC, 74 of which occurred with patients on statins. The
characteristics of the patients are featured in Table 2. Infectious complications occurred
in patients that tended to be older (59.6 ± 15.6 years versus 54.6 ± 16.0 years, p<0.0001),
have greater surgical risk determined through ASA, and were more likely to be diabetic
(21% of patients with an infectious complication versus 12%). Intraoperatively, patients
with a POIC tended to receive more units of RBC (10% of patients with a POIC received
>2 units of RBC versus 3%, p = 0.001) and have longer operations (the POIC group had a
mean length of operation of 3.14 ± 2.0 hours versus a mean length of operation of 2.38 ±
1.4 hours, p < 0.0001). Postoperatively, POIC patients tended to have a longer hospital
length of stay (patients with a POIC had a mean stay of 12.1 days versus 8.6 days).
There were no significant associations between pre-operative WBC, type of case, or
steroid use.
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TABLE 2: Demographic and Clinical Characteristics of Patients with at least one
Postoperative Infectious Complication (POIC)
Demographic and Clinical Data by POIC
With infection
No Infection
p value
Age ± mean SD (yr)
n

59.67 ± 15.66
224

54.62 ± 16.05
2360

20 (9.95%)
1 (0.49%)
180 (89.5%)

196 (9.21%)
34 (1.59%)
1897 (89.18%)

82 (82.8%)
17 (17.1%)

780 (86.9%)
117 (13%)

<0.0001

40 (18%)
181 (81.9%)

207 (8.85%)
2131 (91.15%)

0.319

ASA
1
2
3
4-5

3
32
62
2

73
530
279
15

<0.0001

Diabetes
insulin
oral
no

13
8
78

46
65
786

0.005

Steroids
yes
no

6
93

28
869

0.126

9.26
125

8.48
1224

0.023

89
10

867
30

0.0011

3.14 ±2.037
221

2.38 ±1.45
2339

<0.001

13.73
223

5.3
2347

<0.0001

Race
Black
Other
White
General Surgery
Procedure
yes
no
Emergent
yes
no

Pre-Operative WBC
(103/mm3)
n
Units of RBC
0-2 units
>2 units
Length of Operation (hr)
n
Length of Stay (days)
n

<0.0001
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Primary and Secondary Outcomes
ASA, length of operation, and urgency of case were identified as independent risk factors
for POI and were included in multivariate analysis, shown in Table 3.

TABLE 3. Independent Predictors POIC
Independent variable

AOR

Pre-operative statin use
ASA classification
Length of Operation
Emergency of case

0.978
2.526
2.054
2.855

95% CI
0.584
1.698
1.198
1.568

1.637
3.758
3.52
5.201

p-value
0.932
<0.0001
0.0088
0.0006

Patients receiving statins, when adjusted for ASA classification, length of operation, and
case emergency, had a slightly reduced risk of POI that was not significant [AOR 0.978
(95% CI 0.58 – 1.63, p = 0.93)]. Statin patients had a non-statistically significant
reduction in risk for unadjusted DSSI and WD. Patients receiving statins had an
increased risk of sepsis and septic shock, although these were not statistically significant.
Patients with statins that were diagnosed with PNA had an unadjusted reduced risk of
68% (OR 0.321 CI 0.17 – 0.58, p = 0.0003). However, in the adjusted analysis, patients
receiving statins actually had an increased risk of pneumonia, with an AOR of 1.75,
although this difference was not statistically significant (95% CI 0.93 – 3.30, p = 0.08).
Statin patients had a reduced risk of UTI, with an unadjusted OR of 0.40 (95% CI 0.20 –
0.80, p = 0.01). SSI for patients receiving statins had an unadjusted OR of 0.65 (95% CI
0.43 – 1.00, p = 0.06), but was not statistically significant when adjusted. Patients
receiving statins did have a significant reduction in risk of 30 day postoperative mortality
with an OR of 0.45 (95% CI 0.23 – 0.87, p = 0.019). These results are summarized in
Table 4 and Table 5.
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TABLE 4. Unadjusted Impact of Preoperative Statin use on Secondary Endpoints
Endpoint
Sepsis
Septic Shock
PNA
UTI
SSI
DSSI
WD
30-day Mortality

OR
1.02
2.88
0.321
0.4
0.65
0.35
0.67
0.45

Unadjusted Analysis
95% CI
0.48
2.15
0.37
22.61
0.17
0.58
0.2
0.8
0.43
1
0.095
1.33
0.17
2.6
0.23
0.87

p-value
0.999
0.47
0.0003
0.01
0.06
0.119
0.47
0.019

TABLE 5. Adjusted Impact of Preoperative Statin use on Primary and Secondary
Endpoints
Endpoint
Composite Endpoint
PNA
SSI

AOR
0.978
1.75
1.01

Adjusted Analysis
95% CI
0.58
1.63
0.93
3.3
0.46
2.21

p-value
0.93
0.08
0.97
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Section 8: Discussion
Our results showed that general surgery patients receiving statins had an adjusted
reduction in risk of POIC of 3%, which did not reach statistical significance, and a 55%
reduction in risk in 30 day mortality. The reduction in 30 day postoperative mortality
mirrored the trend published by other authors 23, 24, 73, 80, 84, 86, 94. In addition, we
were able to identify independent risk factors of POIC, which included ASA, length of
operation and urgency of care. We also confirmed that length of stay for patients with a
postoperative infectious complication was over 2.5 times the length of stay for patients
without such a complication.

Similar to the only other study to explore postoperative infectious complications in the
surgical patient (the Coleman study explored the role of statins in cardiac surgery), we
were not able to achieve statistical significance in our sub-group analysis of individual
POIC 82. This was due to inadequate power and would require many more patients to be
enrolled in order to appropriately analyze each type of POIC. However, we were able to
demonstrate similar results on postoperative mortality.

Our study sought to prove that preoperative statin use would result in a reduction of
POIC. In fact, we were unable to demonstrate this effect as profoundly as we had hoped,
despite evidence of statins ability to reduce the severity pneumonia and sepsis 21, 24, 28,
69, 73, 74. It is possible that since our statin group was older, had higher ASA scores,
more diabetics, receiving steroids, and more general surgery procedures, the cohort was
not comparable to the non-statin group. Studies have shown that DM and nutritional
status (more importantly, malnutrition) are risk factors for SSI 96. It is possible that we
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did not account for such determinants of postoperative infectious outcomes like
malnutrition, socioeconomic status, or other unknown risk factors for infection. While
we identified ASA, emergency of case, and length of operation as independent risk
factors, it is entirely possible that we failed to identify other factors not collected in the
ACS NSQIP or that our sample size was not sufficient to identify other contributing
factors.

Other studies have shown a benefit to calculating an APACHE II score for admitted
patients to characterize health status. No APACHE II score was done on admission,
which could have served as another indicator of health status, the way that ASA
classification serves as a marker for risk in surgery. Similarly, a pneumonia severity
index could have been helpful in assessing the severity of the cases of pneumonia.
Of note, a study by Fernandez et al found that statins increased mortality in ICU patients
and felt that this was not due to the effects of statins, but in fact that statins were possibly
a marker of severity in their ICU patients (sicker patients were on statins) 71.
Interestingly, the Fernandez study included both medical and surgical patients admitted to
their ICU. Lastly, CRP levels were not taken and could have been a useful marker of
inflammation, but in a retrospective study, there would not have been any way to collect
that information using the hospital database information and the ACS NSQIP.

Limitations
Retrospective observational cohort studies, by default, are subject to bias as these types
of studies are not as tightly controlled as double-blinded, randomized control trials. We
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tried to account for as much bias and confounders through multivariate logistic
regression. However, the sample size was too small to allow adjustment for all of the
factors know to be associated with postoperative infections. In addition, factors out of our
control (specificity of data into the pharmacy database, variables entered into the ACS
NSQIP) still remain. Other potential uncontrolled confounding variables were the timing
in the administration of other treatments (antibiotics, other vital medications), which may
have differed between groups. Similarly, different surgeons and their surgical outcomes
could potentially impact the results of this study, particularly since we do not have a very
large sample size of patients in each specific postoperative infections outcome. By
making the study multi-centered, we could increase the number of postoperative
infectious events. Likewise, a randomized-control trial could be beneficial, but the ethics
of doing so may be controversial as the association of preoperative statin use and at least
30-day mortality rate has been well documents. Yet, the dosage, type of statin, timing,
and what post-operative infectious complication benefits from stain use remains to be
properly enumerated. We were able to confirm that there was a benefit in 30-day
mortality. However, the role of statins in postoperative infectious complications in the
non-cardiac and general surgery patient remains unknown.
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